Nuvation Bio, Inc. (NUVB) saw its stock price plummet 5.32% in pre-market trading on Thursday, following the release of its second-quarter 2025 financial results. Despite beating revenue expectations, the company's persistent losses and high operating expenses appear to have rattled investors.

The clinical-stage biopharmaceutical company reported Q2 earnings per share (EPS) of -$0.17, in line with analyst consensus estimates. Nuvation Bio's revenue for the quarter came in at $1.238 million, significantly surpassing the IBES estimate of $357.1 thousand. This represents a substantial 236.79% increase from the $1.435 million reported in the same period last year.

However, the company's financial health remains a concern for investors. Nuvation Bio reported a net loss of $59.007 million for the quarter, with operating expenses reaching $65.846 million. The high burn rate, coupled with ongoing losses, likely contributed to the negative market reaction despite the revenue beat. As the company continues to invest heavily in its pipeline of oncology treatments, investors may be growing impatient for signs of profitability or major clinical breakthroughs.